The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs by $7.3 billion over six years.
The "Big 3" PBMs also separately generated an estimated $1.4 billion of income from spread pricing, FTC finds.
The National Association of Chain Drug Stores is praising the Federal Trade Commission's (FTC) unanimous, 5-0, vote on Monday to release the second interim staff report on the FTC's study of big ...
An Alabama lawmaker believes prescription care management should be a legislative priority during the upcoming session.
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
The accused killer of Brian Thompson cited the industry’s failures as his motive for assassinating the UnitedHealth executive ...
UnitedHealth shares a quarterly report for the first time since the death of insurance unit leader Brian Thompson. A look at ...
The city of Meriden, Connecticut, filed a lawsuit in federal court on Monday, accusing 20 companies, including major drug manufacturers such as CVS Health Corp., Eli Lilly and Co., and Novo Nordisk ...
Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...
The Federal Trade Commission found Pharmacy Benefit Managers profited billions by raising the prices of "specialty drugs." ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback